In a post hoc analysis of 260 patients with resectable or borderline resectable pancreatic cancer given neoadjuvant mFOLFIRINOX or PAXG, treatment at centres with higher protocol violation rates was associated with shorter event-free survival (10.3 vs 14.5 months; HR 0.70).
Secondary analysisn = 260
Fosfuri et al. Impact of center-level protocol adherence on neoadjuvant treatment outcome in pancreatic ductal adenocarcinoma